vs

Side-by-side financial comparison of OIL STATES INTERNATIONAL, INC (OIS) and VERACYTE, INC. (VCYT). Click either name above to swap in a different company.

OIL STATES INTERNATIONAL, INC is the larger business by last-quarter revenue ($178.5M vs $140.6M, roughly 1.3× VERACYTE, INC.). VERACYTE, INC. runs the higher net margin — 29.3% vs -65.7%, a 95.0% gap on every dollar of revenue. On growth, VERACYTE, INC. posted the faster year-over-year revenue change (18.5% vs 8.4%). VERACYTE, INC. produced more free cash flow last quarter ($48.8M vs $47.1M). Over the past eight quarters, VERACYTE, INC.'s revenue compounded faster (20.5% CAGR vs 3.3%).

Oil States International, Inc. is an American multinational corporation. It focuses on providing services to oil and gas companies. It is a public company listed on the New York Stock Exchange.

Veracyte Inc. is a leading molecular diagnostics company that develops and commercializes proprietary genomic testing solutions for early, accurate detection of cancer and other complex diseases. Its offerings help healthcare providers make better clinical decisions to improve patient outcomes, with core operations in the U.S. and expanding global market presence across key clinical segments.

OIS vs VCYT — Head-to-Head

Bigger by revenue
OIS
OIS
1.3× larger
OIS
$178.5M
$140.6M
VCYT
Growing faster (revenue YoY)
VCYT
VCYT
+10.1% gap
VCYT
18.5%
8.4%
OIS
Higher net margin
VCYT
VCYT
95.0% more per $
VCYT
29.3%
-65.7%
OIS
More free cash flow
VCYT
VCYT
$1.7M more FCF
VCYT
$48.8M
$47.1M
OIS
Faster 2-yr revenue CAGR
VCYT
VCYT
Annualised
VCYT
20.5%
3.3%
OIS

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
OIS
OIS
VCYT
VCYT
Revenue
$178.5M
$140.6M
Net Profit
$-117.2M
$41.1M
Gross Margin
10.9%
72.5%
Operating Margin
-63.7%
26.4%
Net Margin
-65.7%
29.3%
Revenue YoY
8.4%
18.5%
Net Profit YoY
-873.2%
704.8%
EPS (diluted)
$-1.99
$0.50

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
OIS
OIS
VCYT
VCYT
Q4 25
$178.5M
$140.6M
Q3 25
$165.2M
$131.9M
Q2 25
$165.4M
$130.2M
Q1 25
$159.9M
$114.5M
Q4 24
$164.6M
$118.6M
Q3 24
$174.3M
$115.9M
Q2 24
$186.4M
$114.4M
Q1 24
$167.3M
$96.8M
Net Profit
OIS
OIS
VCYT
VCYT
Q4 25
$-117.2M
$41.1M
Q3 25
$1.9M
$19.1M
Q2 25
$2.8M
$-980.0K
Q1 25
$3.2M
$7.0M
Q4 24
$15.2M
$5.1M
Q3 24
$-14.3M
$15.2M
Q2 24
$1.3M
$5.7M
Q1 24
$-13.4M
$-1.9M
Gross Margin
OIS
OIS
VCYT
VCYT
Q4 25
10.9%
72.5%
Q3 25
22.1%
69.2%
Q2 25
24.2%
69.0%
Q1 25
23.3%
69.5%
Q4 24
23.7%
66.4%
Q3 24
21.7%
68.2%
Q2 24
23.8%
68.1%
Q1 24
21.1%
64.5%
Operating Margin
OIS
OIS
VCYT
VCYT
Q4 25
-63.7%
26.4%
Q3 25
2.9%
17.4%
Q2 25
3.2%
-4.0%
Q1 25
3.5%
2.5%
Q4 24
11.2%
3.5%
Q3 24
-6.3%
10.4%
Q2 24
1.1%
4.0%
Q1 24
-6.7%
-4.8%
Net Margin
OIS
OIS
VCYT
VCYT
Q4 25
-65.7%
29.3%
Q3 25
1.2%
14.5%
Q2 25
1.7%
-0.8%
Q1 25
2.0%
6.2%
Q4 24
9.2%
4.3%
Q3 24
-8.2%
13.1%
Q2 24
0.7%
5.0%
Q1 24
-8.0%
-1.9%
EPS (diluted)
OIS
OIS
VCYT
VCYT
Q4 25
$-1.99
$0.50
Q3 25
$0.03
$0.24
Q2 25
$0.05
$-0.01
Q1 25
$0.05
$0.09
Q4 24
$0.24
$0.07
Q3 24
$-0.23
$0.19
Q2 24
$0.02
$0.07
Q1 24
$-0.21
$-0.02

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
OIS
OIS
VCYT
VCYT
Cash + ST InvestmentsLiquidity on hand
$69.9M
$362.6M
Total DebtLower is stronger
$1.7M
Stockholders' EquityBook value
$573.2M
$1.3B
Total Assets
$883.4M
$1.4B
Debt / EquityLower = less leverage
0.00×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
OIS
OIS
VCYT
VCYT
Q4 25
$69.9M
$362.6M
Q3 25
$67.1M
$315.6M
Q2 25
$53.9M
$219.5M
Q1 25
$66.8M
$186.1M
Q4 24
$65.4M
$239.1M
Q3 24
$46.0M
$274.1M
Q2 24
$25.2M
$235.9M
Q1 24
$24.1M
$209.2M
Total Debt
OIS
OIS
VCYT
VCYT
Q4 25
$1.7M
Q3 25
$1.9M
Q2 25
$1.9M
Q1 25
$124.7M
Q4 24
$124.7M
Q3 24
$124.6M
Q2 24
$124.3M
Q1 24
$135.6M
Stockholders' Equity
OIS
OIS
VCYT
VCYT
Q4 25
$573.2M
$1.3B
Q3 25
$689.0M
$1.3B
Q2 25
$690.6M
$1.2B
Q1 25
$683.4M
$1.2B
Q4 24
$680.7M
$1.2B
Q3 24
$684.8M
$1.2B
Q2 24
$690.4M
$1.1B
Q1 24
$692.3M
$1.1B
Total Assets
OIS
OIS
VCYT
VCYT
Q4 25
$883.4M
$1.4B
Q3 25
$1.0B
$1.4B
Q2 25
$993.7M
$1.3B
Q1 25
$990.7M
$1.3B
Q4 24
$1.0B
$1.3B
Q3 24
$994.1M
$1.3B
Q2 24
$1.0B
$1.2B
Q1 24
$1.0B
$1.2B
Debt / Equity
OIS
OIS
VCYT
VCYT
Q4 25
0.00×
Q3 25
0.00×
Q2 25
0.00×
Q1 25
0.18×
Q4 24
0.18×
Q3 24
0.18×
Q2 24
0.18×
Q1 24
0.20×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
OIS
OIS
VCYT
VCYT
Operating Cash FlowLast quarter
$50.1M
$52.6M
Free Cash FlowOCF − Capex
$47.1M
$48.8M
FCF MarginFCF / Revenue
26.4%
34.7%
Capex IntensityCapex / Revenue
1.7%
2.7%
Cash ConversionOCF / Net Profit
1.28×
TTM Free Cash FlowTrailing 4 quarters
$73.9M
$126.6M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
OIS
OIS
VCYT
VCYT
Q4 25
$50.1M
$52.6M
Q3 25
$30.7M
$44.8M
Q2 25
$15.0M
$33.6M
Q1 25
$9.3M
$5.4M
Q4 24
$18.2M
$24.5M
Q3 24
$28.8M
$30.0M
Q2 24
$10.2M
$29.6M
Q1 24
$-11.4M
$-9.0M
Free Cash Flow
OIS
OIS
VCYT
VCYT
Q4 25
$47.1M
$48.8M
Q3 25
$22.0M
$42.0M
Q2 25
$4.7M
$32.3M
Q1 25
$137.0K
$3.5M
Q4 24
$4.0M
$20.4M
Q3 24
$21.4M
$27.7M
Q2 24
$4.5M
$26.8M
Q1 24
$-21.5M
$-11.1M
FCF Margin
OIS
OIS
VCYT
VCYT
Q4 25
26.4%
34.7%
Q3 25
13.3%
31.8%
Q2 25
2.8%
24.8%
Q1 25
0.1%
3.1%
Q4 24
2.4%
17.2%
Q3 24
12.3%
23.9%
Q2 24
2.4%
23.4%
Q1 24
-12.8%
-11.5%
Capex Intensity
OIS
OIS
VCYT
VCYT
Q4 25
1.7%
2.7%
Q3 25
5.3%
2.1%
Q2 25
6.2%
1.0%
Q1 25
5.7%
1.6%
Q4 24
8.6%
3.5%
Q3 24
4.3%
1.9%
Q2 24
3.1%
2.4%
Q1 24
6.0%
2.2%
Cash Conversion
OIS
OIS
VCYT
VCYT
Q4 25
1.28×
Q3 25
16.15×
2.34×
Q2 25
5.33×
Q1 25
2.94×
0.76×
Q4 24
1.20×
4.80×
Q3 24
1.98×
Q2 24
7.87×
5.16×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

OIS
OIS

Project Driven$112.6M63%
Downhole Technologies$32.1M18%
Completion And Production Services$23.1M13%
Military And Other Products$10.7M6%

VCYT
VCYT

Testing$135.8M97%
Products$3.8M3%
Biopharmaceutical And Other$686.0K0%

Related Comparisons